Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs INB-100 (Primary) ; Cyclophosphamide; Fludarabine
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- 10 Dec 2024 According to an IN8bio media release, this INB-100 trial has been expanded to enroll additional patients at Dose Level (DL) 2, recommended Phase 2 dose (RP2D). Enrollment of additional patients into the expansion cohort is on-going and updated data, are expected to be reported in the first half of 2025.
- 10 Dec 2024 Results published in an IN8bio media release.
- 10 Dec 2024 According to an IN8bio media release, company is looking forward to announcing additional data next year.